Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EPS (Weighted Average and Diluted) (2020 - 2026)

Fulcrum Therapeutics (FULC) has 7 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.25 in Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 10.71% to -$0.25 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.15, a 3733.33% decrease, with the full-year FY2025 number at -$1.18, down 637.5% from a year prior.
  • EPS (Weighted Average and Diluted) reached -$0.25 in Q1 2026 per FULC's latest filing, up from -$0.31 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for FULC hit a ceiling of $0.87 in Q2 2024 and a floor of -$0.83 in Q2 2022.
  • A 5-year average of -$0.33 and a median of -$0.38 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 328.95% in 2024, then tumbled 132.18% in 2025.
  • Tracing FULC's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.47 in 2022, then rose by 14.89% to -$0.4 in 2023, then surged by 32.5% to -$0.27 in 2024, then decreased by 14.81% to -$0.31 in 2025, then rose by 19.35% to -$0.25 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for FULC at -$0.25 in Q1 2026, -$0.31 in Q4 2025, and -$0.31 in Q3 2025.